Gray et al., using multiparametric flow cytometry for analysis of melanoma (MCAM, MCSP) and tumor-infiltrating (ABCB5, CD271, RANK) marker co-expression, found that only RANK-positive cells reflected the effectiveness of BRAF/MEK-targeted therapy with vemurafenib or dabrafenib/trametinib. This evidence concerns the gene ABCB5 and melanoma.